Health Care·Biotechnology·$161.9B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $2.43 | N/A | +7.05% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $2.43 | N/A | +7.05% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management highlighted the positive EPS surprise but did not offer detailed insights into revenue performance or future expectations.
Management expressed satisfaction with the EPS performance.
No specific guidance was provided for future quarters.
Gilead Sciences reported a better-than-expected EPS for the quarter, indicating strong profitability. However, the lack of revenue data and guidance leaves uncertainty about future performance. Investors may be cautious as they await more information on revenue trends and management's outlook.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
FABRINET
Feb 2, 2015